ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.
Bottom Line: To examine gene abnormalities, 83 cases of various types of lung carcinoma were examined by quantitative real-time genomic PCR and immunohistochemistry.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.Show MeSH
Related in: MedlinePlus
Mentions: From the cDNA microarray data, 144 early-stage (pStage I) adenocarcinomas were divided into two groups showing high (n = 22) and low (n = 122) expression of ECT2. As shown in Figure 3, the ECT2 high group showed a significantly poorer outcome in terms of both OS rate and RFS rate. Moreover, multivariate analysis showed that ECT2 overexpression was an independent prognostic factor, similar to vascular invasion (Table 3).
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.